Lung Cancer - Chemotherapy

JANS Article

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC

November 10, 2023 | Aristotle ProtopapasGold ContributorGold Commentor

A manuscript that wil certainly be discussed in lung MDT! The thought of a RCT in these earlier stages may be already in the mind of the sponsors… The authors do not report synergic side...

JANS Article

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC

November 10, 2023 | Aristotle ProtopapasGold ContributorGold Commentor

A manuscript that wil certainly be discussed in lung MDT! The thought of a RCT in these earlier stages may be already in the mind of the sponsors… The authors...

JANS Article

Underutilization of Systemic Therapy in Patients with NSCLC Undergoing Pneumonectomy: A Missed Opportunity for Survival

September 15, 2023 | Mujtaba MubashirGold Contributor

This large-scale analysis of the National Cancer Database (NCDB) highlights some interesting trends in the current use of systemic therapy in patients with NSCLC who undergo pneumonectomy. Current practice patterns...

JANS Article

The American Association for Thoracic Surgery (AATS) 2023 Expert Consensus Document: Staging and Multidisciplinary Management of Patients with Early-Stage Non-Small Cell Lung Cancer

June 15, 2023 | Cameron LindGold Contributor

A new expert consensus on diagnosis, staging, and therapy for early-stage non-small cell lung cancer patients has been released. The experts recommend CT and PET imaging as a necessary part...

JANS Article

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

May 26, 2022 | Aristotle ProtopapasGold ContributorGold Commentor

No statistical significance ,between the two arms, regarding the OVERALL survival in this RCT funded by the supplier and manufacturer of the immunotherapy in question….

...
JANS Article

Nivolumab Plus Ipilimumab in Lung Cancer With a High Tumor Mutational Burden

May 31, 2018 | Mark FergusonGold Contributor

This randomized trial evaluating the relative efficacy of immunotherapy and chemotherapy in patients with recurrent or metastatic disease, immunotherapy was associated with significantly better progression-free survival. Tumor mutational burden was...

JANS Article

Pembrolizumab Plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

May 30, 2018 | Mark FergusonGold Contributor

The addition of pembrolizumab (targeting PD-1) to standard chemotherapy substantially improved time to progression and overall survival compared to chemotherapy alone in patients with metastatic lung cancer.

...
JANS Article

Concurrent Versus Sequential Chemoradiation Therapy in Completely Resected Pathologic N2 Non-Small Cell Lung Cancer: Propensity-Matched Analysis of the National Cancer Data Base

April 13, 2018 | Mark FergusonGold Contributor

The authors found that adjuvent chemoradiotherapy after resection of N2 NSCLC was more effective if given sequentially than concomitantly.

...
JANS Article

In Global News: Weaving Devices for CHD by Hand, Sodas and CAD, and Rapid Deployment Versus Conventional Valves

March 30, 2018 | Grahame Rush

Patient CareHigher risk of death from coronary artery disease was noted for Americans who drank higher quantities of sugary beverages but not for those who ate more sugary foods. Drugs...

JANS Article

In Global News: Smallest Heart Valve for Infants, a Modified TAVR Valve for TMVR, and Thoracic Outlet Surgery Fashion

March 9, 2018 | Claire VernonGold Contributor

Patient Care Carter Capps, a pitcher for professional baseball team the San Diego Padres, has made himself a necklace out of the rib surgeons removed during his thoracic outlet surgery....

JANS Article

Lung Cancer Awareness Month—A Lot of Progress, But More Work Needs to Be Done

October 24, 2017 | Mark FergusonGold Contributor

A useful reminder of the substantial progress that has been made and the continuing challenges that we face in fighting this terrible disease.

...
JANS Article

Scientific Advances in Thoracic Oncology 2016

August 2, 2017 | Mark FergusonGold Contributor

This is an excellent summary of progress during the past year in all aspects of lung cancer, from prevention/detection through molecular therapies and future perspectives. Each section is written by...

JANS Article

The 5000% case: a glimpse into the financial issue of lung cancer treatment

May 5, 2016 | Marcelo JimenezBronze Contributor

This is an outstanding and provocative editorial comment concerning treatment costs of lung cancer based on an article published in the last issue of the European Respiratory Journal. It reveals...

LOAD MORE
ADVERTISE ON CTSNET